Dare Bioscience, Inc. — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020; filed May 14, 2020. Dare is a clinical-stage women’s-health biopharmaceutical company with no approved or commercialized products. It reported no product revenue.
Financial results and liquidity
| Metric | Q1 2020 | Q1 2019 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $4.25 million | $3.08 million |
| Net loss | $4.25 million | $3.05 million |
| Loss per share, basic and diluted | $0.18 | $0.27 |
| Operating cash flow | $(6.60) million | $(3.31) million |
| Cash and cash equivalents at period-end | $5.05 million | $4.78 million at Dec. 31, 2019 |
| Working capital at period-end | $4.6 million | Not stated for the comparable period |
| Total liabilities | $7.00 million | $7.00 million at Dec. 31, 2019 |
There was no meaningful operating margin because the company had no revenue. General and administrative expense rose $585,000, primarily from professional services and personnel; research and development rose $686,000, reflecting development activity, including the acquired microchip contraceptive program, partly offset by grant funding. The greater net loss was partly offset in per-share terms by a higher weighted-average share count.
Q1 financing provided $6.89 million: approximately $5.2 million net from ATM share sales and $1.7 million from warrant exercises. Share count increased to 24.70 million at March 31 from 19.68 million at year-end. Current liabilities were $4.72 million; reported lease liabilities totaled approximately $689,000 and contingent consideration was $1.0 million. The $1.0 million Bayer upfront fee was deferred revenue, not recognized as Q1 revenue.
Material developments and outlook
- Going concern: Management said cash was insufficient for at least the next 12 months from issuance of the financial statements and disclosed substantial doubt about the company’s ability to continue as a going concern. It expects continued losses and operating cash outflows and needs substantial additional capital.
- COVID-19: The pandemic could raise development costs and delay trials, enrollment, clinical supply, regulatory work, and access to capital. Dare postponed the planned start of the Ovaprene pivotal study and was reassessing timing for the Sildenafil Cream trial.
- Development plans: Management expected to initiate the DARE-BV1 Phase 3 study in the second half of 2020, with topline results before year-end and a possible NDA filing in early 2021 if studies were successful. It expected DARE-HRT1 Phase 1 topline results by year-end 2020; Sildenafil Cream Phase 2b topline data by year-end 2021; and Ovaprene pivotal-study topline data by year-end 2022. These were forward-looking estimates subject to COVID-19 and funding risks.
- Bayer/Ovaprene: Bayer paid a nonrefundable $1.0 million upfront fee. Bayer may, at its sole discretion, pay an additional $20.0 million to make its U.S. license effective. Further payments, including up to $310 million in milestones and tiered royalties, depend on future development and commercial outcomes; the agreement also gives Bayer termination rights.
- Subsequent funding: After quarter-end, Dare received approximately $2.0 million of ATM proceeds through May 12, approximately $428,000 of NIH grant funding, and a $367,000 PPP loan. It also established a discretionary equity line of up to $15 million, subject to conditions, share limits, market prices, and potential dilution. PPP forgiveness was not assured.
Operating performance should be viewed in the context of a development-stage business: there is no product revenue, profitability is not established, and the company depends on external financing, grants, and potential partnerships. Equity issuance can dilute existing holders; trial outcomes, regulatory approval, partner decisions, and COVID-related disruption remain significant risks. Management reported disclosure controls were effective as of March 31, 2020; no material pending legal proceedings were disclosed.
Important facts for investors to verify
- Cash runway and financing needs against actual subsequent cash use, ATM sales, equity-line availability, and any further capital raised.
- Whether the conditional Bayer $20 million payment is made and whether the Ovaprene license becomes effective.
- Actual timing, enrollment, costs, and results for DARE-BV1, Ovaprene, Sildenafil Cream, and DARE-HRT1, including COVID-related changes.
- Potential dilution from ATM and equity-line sales, warrant exercises, and the increase in shares outstanding after March 31.
- PPP loan forgiveness status and the timing and eligibility of grant reimbursements, including deferred grant funding.